Loading…
Lithium and Triiodothyronine Augmentation of Antidepressants
Objective: To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone. Methods: We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compa...
Saved in:
| Published in: | Canadian journal of psychiatry 2006-10, Vol.51 (12), p.791-793 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53 |
| container_end_page | 793 |
| container_issue | 12 |
| container_start_page | 791 |
| container_title | Canadian journal of psychiatry |
| container_volume | 51 |
| creator | Joffe, Russell T Sokolov, Stephen TH Levitt, Anthony J |
| description | Objective:
To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.
Methods:
We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.
Results:
All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences.
Conclusion:
There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo. |
| doi_str_mv | 10.1177/070674370605101209 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_222802960</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_070674370605101209</sage_id><sourcerecordid>1168745921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53</originalsourceid><addsrcrecordid>eNp9kE1rwzAMhs3YWLtuf2CHEQY7ZpXtOE5gl1L2BYVdunNwYqd1aezOdg7993NooIfBdJBAPHolvQjdY3jGmPM5cMh5RmMGhgETKC_QFGclTwEwu0TTAUgHYoJuvN9BDEKKazTBHOcFYdkUvax02Oq-S4SRydppbaUN26OzRhuVLPpNp0wQQVuT2DZZmKClOjjlvTDB36KrVuy9uhvrDH2_va6XH-nq6_1zuVilTZaRkFKZy4xRWUOuMgqEqqYlnBIuQcVeXeAS8ly2BOqyrBXDVEjCsGpogWndMjpDjyfdg7M_vfKh2tnembiyIvEhIGUOESInqHHWe6fa6uB0J9yxwlANflV__YpDD6NyX3dKnkdGgyLwNALCN2LfOmEa7c9cQaM0FJGbnzgvNup83j-rfwHLs35-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222802960</pqid></control><display><type>article</type><title>Lithium and Triiodothyronine Augmentation of Antidepressants</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Joffe, Russell T ; Sokolov, Stephen TH ; Levitt, Anthony J</creator><creatorcontrib>Joffe, Russell T ; Sokolov, Stephen TH ; Levitt, Anthony J</creatorcontrib><description>Objective:
To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.
Methods:
We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.
Results:
All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences.
Conclusion:
There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo.</description><identifier>ISSN: 0706-7437</identifier><identifier>EISSN: 1497-0015</identifier><identifier>DOI: 10.1177/070674370605101209</identifier><identifier>PMID: 17168254</identifier><identifier>CODEN: CJPSDF</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antidepressants ; Antidepressive Agents - metabolism ; Antidepressive Agents - pharmacokinetics ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Depression ; Depressive Disorder, Major - drug therapy ; Double-Blind Method ; Drug Administration Schedule ; Drug Resistance ; Drug Synergism ; Drug Therapy, Combination ; Female ; Humans ; Lithium ; Lithium Carbonate - metabolism ; Lithium Carbonate - pharmacokinetics ; Lithium Carbonate - therapeutic use ; Male ; Medical sciences ; Mental disorders ; Mood disorders ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Thyroid gland ; Triiodothyronine - pharmacology ; Triiodothyronine - therapeutic use</subject><ispartof>Canadian journal of psychiatry, 2006-10, Vol.51 (12), p.791-793</ispartof><rights>2006 Canadian Psychiatric Association</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Canadian Psychiatric Association Oct 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53</citedby><cites>FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18311708$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17168254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joffe, Russell T</creatorcontrib><creatorcontrib>Sokolov, Stephen TH</creatorcontrib><creatorcontrib>Levitt, Anthony J</creatorcontrib><title>Lithium and Triiodothyronine Augmentation of Antidepressants</title><title>Canadian journal of psychiatry</title><addtitle>Can J Psychiatry</addtitle><description>Objective:
To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.
Methods:
We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.
Results:
All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences.
Conclusion:
There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - metabolism</subject><subject>Antidepressive Agents - pharmacokinetics</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Depression</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Lithium</subject><subject>Lithium Carbonate - metabolism</subject><subject>Lithium Carbonate - pharmacokinetics</subject><subject>Lithium Carbonate - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Mood disorders</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Thyroid gland</subject><subject>Triiodothyronine - pharmacology</subject><subject>Triiodothyronine - therapeutic use</subject><issn>0706-7437</issn><issn>1497-0015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE1rwzAMhs3YWLtuf2CHEQY7ZpXtOE5gl1L2BYVdunNwYqd1aezOdg7993NooIfBdJBAPHolvQjdY3jGmPM5cMh5RmMGhgETKC_QFGclTwEwu0TTAUgHYoJuvN9BDEKKazTBHOcFYdkUvax02Oq-S4SRydppbaUN26OzRhuVLPpNp0wQQVuT2DZZmKClOjjlvTDB36KrVuy9uhvrDH2_va6XH-nq6_1zuVilTZaRkFKZy4xRWUOuMgqEqqYlnBIuQcVeXeAS8ly2BOqyrBXDVEjCsGpogWndMjpDjyfdg7M_vfKh2tnembiyIvEhIGUOESInqHHWe6fa6uB0J9yxwlANflV__YpDD6NyX3dKnkdGgyLwNALCN2LfOmEa7c9cQaM0FJGbnzgvNup83j-rfwHLs35-</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Joffe, Russell T</creator><creator>Sokolov, Stephen TH</creator><creator>Levitt, Anthony J</creator><general>SAGE Publications</general><general>Canadian Psychiatric Association</general><general>SAGE PUBLICATIONS, INC</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M3G</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20061001</creationdate><title>Lithium and Triiodothyronine Augmentation of Antidepressants</title><author>Joffe, Russell T ; Sokolov, Stephen TH ; Levitt, Anthony J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - metabolism</topic><topic>Antidepressive Agents - pharmacokinetics</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Depression</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Lithium</topic><topic>Lithium Carbonate - metabolism</topic><topic>Lithium Carbonate - pharmacokinetics</topic><topic>Lithium Carbonate - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Mood disorders</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Thyroid gland</topic><topic>Triiodothyronine - pharmacology</topic><topic>Triiodothyronine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joffe, Russell T</creatorcontrib><creatorcontrib>Sokolov, Stephen TH</creatorcontrib><creatorcontrib>Levitt, Anthony J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Canadian journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joffe, Russell T</au><au>Sokolov, Stephen TH</au><au>Levitt, Anthony J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lithium and Triiodothyronine Augmentation of Antidepressants</atitle><jtitle>Canadian journal of psychiatry</jtitle><addtitle>Can J Psychiatry</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>51</volume><issue>12</issue><spage>791</spage><epage>793</epage><pages>791-793</pages><issn>0706-7437</issn><eissn>1497-0015</eissn><coden>CJPSDF</coden><abstract>Objective:
To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.
Methods:
We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.
Results:
All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences.
Conclusion:
There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>17168254</pmid><doi>10.1177/070674370605101209</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0706-7437 |
| ispartof | Canadian journal of psychiatry, 2006-10, Vol.51 (12), p.791-793 |
| issn | 0706-7437 1497-0015 |
| language | eng |
| recordid | cdi_proquest_journals_222802960 |
| source | SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list) |
| subjects | Adult Adult and adolescent clinical studies Antidepressants Antidepressive Agents - metabolism Antidepressive Agents - pharmacokinetics Antidepressive Agents - therapeutic use Biological and medical sciences Depression Depressive Disorder, Major - drug therapy Double-Blind Method Drug Administration Schedule Drug Resistance Drug Synergism Drug Therapy, Combination Female Humans Lithium Lithium Carbonate - metabolism Lithium Carbonate - pharmacokinetics Lithium Carbonate - therapeutic use Male Medical sciences Mental disorders Mood disorders Neuropharmacology Pharmacology. Drug treatments Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Thyroid gland Triiodothyronine - pharmacology Triiodothyronine - therapeutic use |
| title | Lithium and Triiodothyronine Augmentation of Antidepressants |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A20%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lithium%20and%20Triiodothyronine%20Augmentation%20of%20Antidepressants&rft.jtitle=Canadian%20journal%20of%20psychiatry&rft.au=Joffe,%20Russell%20T&rft.date=2006-10-01&rft.volume=51&rft.issue=12&rft.spage=791&rft.epage=793&rft.pages=791-793&rft.issn=0706-7437&rft.eissn=1497-0015&rft.coden=CJPSDF&rft_id=info:doi/10.1177/070674370605101209&rft_dat=%3Cproquest_cross%3E1168745921%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-3d6d453db06e43023ecf27327d0eb06b819066df20b99be513ad251ec3813bf53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222802960&rft_id=info:pmid/17168254&rft_sage_id=10.1177_070674370605101209&rfr_iscdi=true |